...
首页> 外文期刊>The Canadian journal of cardiology >Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.
【24h】

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.

机译:替罗非班与氯吡格雷和阿司匹林合用可减少经皮冠状动脉介入治疗ST抬高型心肌梗死后不良心血管事件:一项随机试验的荟萃分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Current guidelines deemed usefulness of routine early glycoprotein IIb/IIIa inhibitor (GPI) administration in ST-elevation myocardial infarction (STEMI) before primary percutaneous coronary intervention (PCI) with dual antiplatelet therapy as uncertain. We aimed to examine the current evidence for the use of tirofiban, a nonpeptide glycoprotein IIb/IIIa inhibitor, in STEMI patients treated with dual antiplatelet therapy. We performed systematic searches of MEDLINE, EMBASE, and CENTRAL databases for randomized controlled trials (RCTs) of tirofiban use in STEMI patients treated with aspirin and clopidogrel which reported clinical and/or angiographic outcomes after primary PCI. Data were combined using random effect and fixed effect models for heterogeneous and homogeneous outcomes respectively using Review Manager 5 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). Six randomized controlled trials were eligible for the inclusion; involving 708 patients in tirofiban group and 721 control subjects. Routine tirofiban use decreased the major adverse cardiovascular events (odds ratio [OR] 0.50; 95% confidence interval [CI], 0.26-0.94). Corrected thrombolysis in myocardial infarction (TIMI) frame count was also reduced with tirofiban (mean difference -8.48 [95% CI, -12.62 to -4.34]). There were no significant differences in the rates of postprocedure TIMI flow grade 3 and TIMI myocardial perfusion/blush grade 3, major bleeding by TIMI criteria, or mortality in the 2 groups. Current analysis of available studies suggests that routine and early tirofiban use before primary PCI may decrease the major cardiovascular events in STEMI patients treated with aspirin and clopidogrel without any significant increase in major bleeding. An adequately powered randomized trial is urgently needed to confirm the above findings and estimate the effect size.
机译:目前的指南认为,在初次经皮冠状动脉介入治疗(PCI)和双重抗血小板治疗之前,常规早期糖蛋白IIb / IIIa抑制剂(GPI)在ST抬高型心肌梗死(STEMI)中的有用性尚不确定。我们的目的是检查在接受双重抗血小板治疗的STEMI患者中使用非肽糖蛋白IIb / IIIa抑制剂替罗非班的最新证据。我们对MEDLINE,EMBASE和CENTRAL数据库进行了系统搜索,以研究经阿司匹林和氯吡格雷治疗的STEMI患者中替罗非班使用的随机对照试验(RCT),这些患者报告了原发PCI后的临床和/或血管造影结果。分别使用Review Manager 5(Nordic Cochrane中心,Cochrane协作,2008年)使用随机效应和固定效应模型分别针对异质和均质结局合并数据。六项随机对照试验符合纳入条件。替罗非班组708名患者和721名对照对象。常规使用替罗非班可减少主要的不良心血管事件(几率[OR]为0.50; 95%置信区间[CI]为0.26-0.94)。替罗非班也减少了心肌梗死(TIMI)帧数中的溶栓纠正(平均差异为-8.48 [95%CI,-12.62至-4.34])。两组的术后TIMI血流3级和TIMI心肌灌注/腮红3级,以TIMI标准为基准的大出血或死亡率无显着差异。目前对现有研究的分析表明,在进行初次PCI之前常规和早期使用替罗非班可减少接受阿司匹林和氯吡格雷治疗的STEMI患者的主要心血管事件,而不会增加大出血。迫切需要有足够能力的随机试验来证实上述发现并估计疗效大小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号